Skip to main content
Vyome Holdings, Inc logo

Vyome Holdings, Inc — Investor Relations & Filings

Ticker · HIND ISIN · US67424L2097 US Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2025-07-18 Proxy Solicitation & In…
Country US United States of America
Listing US HIND

About Vyome Holdings, Inc

https://www.reshapelifesciences.com/oba…

Vyome Holdings, Inc. is a clinical-stage biotechnology company focused on developing a portfolio of assets for immuno-inflammatory and potential orphan diseases. The company utilizes an artificial intelligence (AI)-driven platform to accelerate its research and development pipeline. Its operations are structured to leverage innovation and R&D capabilities across both the United States and India.

Recent filings

Filing Released Lang Actions
425 Filing
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a letter to stockholders urging them to vote in favor of proposals related to a special meeting. It references a proxy statement filed earlier and discusses proposals including issuance of shares, sale of assets, and amendments to the certificate of incorporation in connection with a transaction. The filing is pursuant to Rule 425 and Rule 14a-12, which are related to proxy solicitation and merger communications. The document does not contain financial statements or detailed financial analysis but is focused on soliciting votes for merger-related proposals. This matches the description of Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters and it is not a report publication announcement but a solicitation letter. Therefore, the correct classification is PSI with high confidence.
2025-07-18 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by ReShape Lifesciences Inc. dated July 15, 2025. It includes a Regulation FD Disclosure and references an attached investor presentation (Exhibit 99.1). The content discusses a proposed merger and asset sale, proxy solicitation information, and forward-looking statements. The document does not contain financial statements or detailed financial analysis but rather serves as a current report disclosing material events and furnishing an investor presentation. It is not an annual or quarterly report, audit report, earnings release, or proxy solicitation statement itself. The primary purpose is to disclose material information pursuant to SEC rules and to furnish an investor presentation. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2025-07-15 English
425 Filing
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by ReShape Lifesciences Inc. dated July 15, 2025. It includes a Regulation FD Disclosure under Item 7.01, which is used to furnish information such as investor presentations. The text explicitly states that Exhibit 99.1 contains investor presentation slides, which are attached and incorporated by reference. The content of the exhibit is a detailed investor presentation about Vyome Therapeutics and the proposed merger with ReShape Lifesciences. The document also references the joint proxy statement/prospectus related to the merger and asset sale, but the main content here is the investor presentation slides. Since the document is a Form 8-K furnishing an investor presentation and the presentation slides are attached as Exhibit 99.1, the appropriate classification is Investor Presentation (IP). The document is not a full annual or quarterly report, nor is it a proxy solicitation or merger filing itself, but rather a current report furnishing an investor presentation. Confidence is high given the clear identification of the presentation and the nature of the filing.
2025-07-15 English
8-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by ReShape Lifesciences Inc. dated June 27, 2025. It reports the entry into a material definitive agreement, specifically a promissory note related to a merger agreement. The content focuses on a financing arrangement and related terms, not on full financial statements or earnings. The document is a regulatory announcement of a material event rather than a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP) as it details a financing activity (loan/promissory note) related to a merger transaction.
2025-07-03 English
425 Filing
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a press release by ReShape Lifesciences Inc. announcing strategic cost reductions and providing an update on a merger agreement and asset purchase agreement. It references a scheduled shareholder meeting to vote on these transactions and mentions that a joint proxy statement/prospectus and other relevant documents have been filed with the SEC and provided to stockholders. The document explicitly states it is filed pursuant to Rule 425 under the Securities Act of 1933 and Rule 14a-12 under the Securities Exchange Act of 1934, which are rules related to proxy solicitation and merger communications. The content focuses on merger updates, shareholder meeting scheduling, and solicitation information rather than the merger agreement itself or detailed merger documents. It does not contain financial statements or detailed financial analysis but rather an update and announcement related to merger activities and proxy solicitation. Therefore, the document fits best into the category of Proxy Solicitation & Information Statement (PSI), as it is related to materials sent to shareholders to provide information and request votes for meetings concerning the merger and asset sale.
2025-06-26 English
424B3 Filing
Merger & Acquisition Classification · 100% confidence The document is a detailed proxy/information statement-prospectus related to a merger proposal between ReShape Lifesciences Inc. and Vyome Therapeutics Inc. It includes information about the merger agreement, asset purchase agreement, promissory note, stockholder meeting details, voting proposals, and regulatory disclosures. The text references Form S-4, which is a registration statement used for mergers and acquisitions, and it serves as both a proxy statement and an information statement for stockholders to vote on the merger and related proposals. The document is not a simple announcement but a comprehensive solicitation and disclosure document related to a merger transaction. This fits the definition of a Merger & Acquisition filing (MA), which includes merger communications and proxy statements related to mergers.
2025-06-24 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.